Viron's R&D efforts are currently focused on 4 development programs.

100 series

Presently, the 100 Series Program contains a single protein, VT-111, which recently completed a Phase IIa clinical trial in ACS patients. VT-111 is a 55 kilodalton secreted glycoprotein and is a serine proteinase inhibitor (serpin).  VT-111 has demonstrated favorable safety in Phase IIa and Phase I trials as well as numerous preclinical studies.

200 Series

In order to interrupt the recruitment and infiltration of leukocytes into inflamed tissue, Viron is developing potent inhibitors of chemokine activity. These inhibitors function in a unique manner by physically binding to chemokines through high-affinity non-covalent interaction and are referred to as Chemokine Binding Proteins (CBPs).

The 200 Series Program contains one highly effective Chemokine Binding Protein. Derived from poxviral genomes, this protein has demonstrated affinity to human chemokines and can inhibit the interaction between chemokines and chemokine receptors.

300 Series

The infiltration of leukocytes into infected and injured tissues is further mediated by pro-inflammatory cytokines within the human body. While the cytokine family consists of a diverse set of proteins that regulate numerous biological functions, several cytokines are known to be specifically released into the bloodstream during the onset and progression of inflammation. Such pro-inflammatory cytokines include IL-1β, IL-2, IFN-γ, IL-6, IL-8 and TNF-α. Similar to the VT-200 program, Viron's therapeutic approach in the VT-300 program is to block the signaling mediated by pro-inflammatory cytokines leading to the onset of leukocyte infiltration and inflammatory disease.

At present, the VT-300 program contains three Cytokine Binding Proteins at various stages of preclinical development and a viral CD30 protein licensed from the University of Cambridge.

900 Series:  PROSPECT^TM Discovery Program

Viron's product pipeline is sustained through the identification of novel candidates and therapies by a dynamic in-house discovery program. PROSPECT^TM, PROtein Screen for Pathogen-Evolved Combination Therapeutics, is a proprietary leading edge platform with the ability to identify high quality drug candidates.  The PROSPECT^TM high throughput program is a streamlined process that focuses on the identification of new pipeline molecules that are of commercial interest to the pharmaceutical industry.